Get the Stockscreener App
11.95
3.78%
0.435
Amneal Pharmaceuticals Inc stock is traded at $11.95, with a volume of 2.65M.
It is up +3.78% in the last 24 hours and up +16.13% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$11.52
Open:
$11.5
24h Volume:
2.65M
Relative Volume:
1.60
Market Cap:
$3.76B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-17.56
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.66%
1M Performance:
+16.13%
6M Performance:
+64.37%
1Y Performance:
+43.63%
1-Day Range:
$11.50
$12.05
1-Week Range:
$11.39
$12.05
52-Week Range:
$6.685
$12.12
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.95 | 3.62B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
122.06 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.82 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs - AOL.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - TradingView
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - FinancialContent
Ted Nark Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Is Amneal Pharmaceuticals Inc. stock trading near support levelsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
Amneal Pharmaceuticals Insider Sold Shares Worth $586,000, According to a Recent SEC Filing - MarketScreener
Multi asset correlation models including Amneal Pharmaceuticals Inc.Trade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneWeekly Risk Report & AI Powered Market Entry Strategies - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedVolume Spike & Fast Exit Strategy with Risk Control - newser.com
Amneal gets FDA nod for Iohexol Injection - MSN
Real time breakdown of Amneal Pharmaceuticals Inc. stock performancePortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayMarket Weekly Review & Weekly High Conviction Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutPortfolio Performance Summary & Weekly High Return Stock Opportunities - newser.com
Why The Narrative Around Amneal Is Shifting Amid Analyst Revisions and Recent FDA Approvals - Yahoo Finance
Amneal Pharmaceuticals (AMRX): Valuation Perspective After FDA Greenlight for First Generic Omnipaque and Raised Guidance - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock By Investing.com - Investing.com Australia
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Amneal gets FDA nod for Iohexol Injection (AMRX:NASDAQ) - Seeking Alpha
FDA approves Amneal’s generic iohexol injection for imaging procedures - Investing.com
Amneal Receives U.S. FDA Approval for Iohexol Injection - The Manila Times
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):